A Study of LY3471851 in Healthy Participants

Nektar Therapeutics

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: LY3471851

Study type: Interventional

Funder types: Industry

Identifiers

NCT04133116

17414

J1P-MC-KFAI (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 7 weeks for each participant.

Enrollment: 36 patients

Sex: All

Ages: 20 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are healthy males or females, as determined by medical history and physical examination
• Are first generation Japanese or are Caucasian
• Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, at the time of screening

Exclusion criteria

• Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study
• Have an abnormal blood pressure and/or pulse rate as determined by the investigator
• Regularly use known drugs of abuse and/or show positive findings on drug screening
• Are immunocompromised per investigator judgment

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 2 patient groups, including a placebo group

LY3471851

Experimental group

Description:

Participants received single doses of 450 microgram (μg), 900 μg or 1800 μg LY3471851 administered subcutaneously (SC).

Treatment:

Drug: LY3471851

Placebo

Placebo Comparator group

Description:

Placebo matching LY3471851 administered SC.

Treatment:

Drug: Placebo